BioCentury
ARTICLE | Clinical News

Ryzodeg insulin degludec/insulin aspart regulatory update

October 22, 2012 7:00 AM UTC

EMA's CHMP recommended approval of an MAA from Novo Nordisk for Ryzodeg insulin degludec/insulin aspart to treat Type I and II diabetes. The product is under review by FDA, with a meeting of the Endoc...